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Primary cardiac sarcoma is a rare clinical entity, with an incidence of 0.0001% in collected autopsy series. The majority of the
literature describes a uniformly dismal prognosis with a median survival of only 6 months for these aggressive tumors. Standard
surgery, adjuvant chemotherapy, and radiotherapy have been consistently unsuccessful. Early heart transplantation and novel ra-
diation therapy approaches may oﬀer a survival beneﬁt in nonmetastatic tumors, but up to 80% of the patients present with
systemic metastasis at diagnosis. Though several chemotherapeutic regimens have been tried, the role of chemotherapy is not well
established and outcome data available is minimal. Liposomal doxorubicin (PLD) has been shown to be useful in the treatment of
soft tissue sarcomas, and our case supports its use in cardiac angiosarcoma.
Copyright © 2006 D. Kodali and K. Seetharaman. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
CASE REPORT
A 66-year old woman presented in July 1999 with 2-week
history of ﬂu-like illness and progressive exertional dyspnea.
S h ew a sf o u n dt oh a v eac a r d i a cm a s so nt r a n s e s o p h a g e a l
echocardiogram. MRI-magnetic resonance imaging revealed
a 3.5/4/4-cm mass in the right atrium and ventricle ex-
tending into the anterior superior mediastinum. The patient
underwent sternotomy and exploration, and the mass was
found to be in the atrioventricular junction. Biopsy revealed
a high-grade angiosarcoma. Staging evaluation revealed a
pulmonary metastasis in the left base posteriorly. Her per-
formance was 2 on the ECOG scale. After detailed discussion
oftreatmentoptions,thepatientoptedforminimalinterven-
tion with minimal toxicity. Liposomal doxorubicin has been
used in soft tissue sarcoma and is well tolerated; hence she
wastreatedwithDoxil40–50mg/m2q4weeksfortotal11cy-
cles. She had an excellent clinical response after 2 cycles and
radiological response after the third cycle (Figures 1, 2). She
enjoyed good quality life and had no signiﬁcant side eﬀects
from chemotherapy. However, she relapsed with extensive
pulmonary disease after 15 months. Thereafter the patient
received two cycles of combination chemotherapy consist-
ing of MAID regimen (mesna, adriamycin, ifosfamide, and
dacarbazine) with minimal response. The patient eventually
succumbed to metastatic disease 16 months after her initial
diagnosis.
DISCUSSION
Twenty ﬁve percent of primary cardiac tumors in adults are
malignant. Sarcomas represent the commonest histology, ac-
counting for 20% of all cardiac neoplasms. Still, primary car-
diac sarcoma is a rare clinical entity, with an incidence of
0.0001% in collected autopsy series [1]. The low incidence of
primary cardiac sarcomas reﬂects the overall low incidence
of sarcomas in the general population and the small percent-
a g eo fb o d yw e i g h to fh e a r t( 0 .5%) compared with muscle
(40%). Angiosarcomas are the commonest cardiac sarcomas
and make up 33% of cases.
Themajorityofcardiacsarcomasoccurbetweenthethird
andﬁfthdecadesoflifewithamalepreponderance(M : Fra-
tio 2 : 1). Primary cardiac sarcoma seldom causes symptoms
until late in the course. Most common symptoms include
dyspnea, chest pain, CHF, palpitation, fever, and myalgia.
The clinical presentation is often found to mimic the more
common cardiopulmonary diseases, usually valvular heart
diseases, although the most frequent presentation is that of
right-sided congestive heart failure. Case reports in the liter-
ature describe a variety of clinical manifestations which in-
clude arrhythmia, vena caval obstruction, pericardial eﬀu-
sion with or without features of tamponade and conduction
disturbances.Incontrastwithbenigntumors,usuallylocated
in the left atrium, malignant tumors are found almost exclu-
sively in the right heart, particularly in the right atrium.2 Sarcoma
Figure 1: Cardiac mass on CT scan before chemotherapy.
Figure 2: Cardiac mass on CT scan after chemotherapy.
Most reported series of cardiac sarcomas describe pa-
tients with primary cardiac sarcomas and response to treat-
ment and survival is anecdotal. Complete resection of car-
diac sarcoma is diﬃcult, in view of the location and extent
of involvement. Often tumors are so large at the time of the
operationthatcompleteresectioncannotbedone.Moreover,
up to 80% of patients present with distant metastasis at di-
agnosis [2]. In general, recommendations for the treatment
of nonmetastatic cardiac sarcoma include exploration for
local control of the primary tumor, to relieve obstructive
symptoms and to prolong disease-free survival. Combined
modality approach has been reported to be successful in few
cases [3].
Cardiac sarcomas generally have a dismal prognosis with
a median survival of only 6 months [4]. Applying the gen-
eral principles of treatment of soft tissue sarcomas occurring
anywhere else in the body, the most critical element is com-
plete surgical resection; however, the location itself is more
diﬃcult for obtaining an adequate margin of resection. The
emphasis is on early detection and diagnosis. Patients with
complete resection have a survival of 24 months compared
with 10 months in those with incomplete resection [5]. Or-
thotopic heart transplantation could allow complete resec-
tion of cardiac tumors and has been performed in selected
patients. However, most are not transplanted because of the
high risk of tumor recurrence or metastasis and the possible
enhancement of tumor growth by immunosuppressive drugs
[6, 7].
The use of radiotherapy is also restricted in many ways.
The typical dose of radiation for sarcomas at most sites is
6000cgy to 6500cgy following complete resection of the sar-
coma. In unresectable lesions the dose of radiation is often
increased to 7000cgy. Such high doses are not well tolerated
by the heart. At a dose of 4000cgy the incidence of pericardi-
tis is approximately 40%. Hyperfractionated radiotherapy
(7050cgy)alongwitharadiosensitizer(5-iododeoxyuridine)
has been shown to eradicate the tumor in a few cases for lo-
coregional control, after surgical resection in nonmetastatic
tumors [2].
The role of adjuvant chemotherapy after surgically re-
sected cardiac sarcoma remains controversial. Some of the
chemotherapeutic regimens used in the past include DECAV,
DTIC, CYVADIC, and VAPAC with variable beneﬁt. There
is some evidence to support adjuvant chemotherapy to re-
lievesymptomsandprolongsurvivalaspartofthecombined
modalityapproach[5].Whileotherstudies,whichcompared
various chemotherapeutic regimes (cyclophosphamide, vin-
cristine, dacarbazine, ifosfamide, methotrexate, vincristine,
doxorubicin), concluded that postoperative chemotherapy
failed to modify the natural course of patients with re-
sected cardiac sarcomas [8]. There has been an isolated re-
port of a cardiac angiosarcoma that responded to multidis-
ciplinary treatment with recombinant interleukin-2, postop-
erative chemotherapy, and radiation in spite of incomplete
resection [9]. No distant metastasis was noted in the case re-
port.
In our case the patient had a soft tissue mass situ-
ated between the right atrium and right ventricle and ex-
tending into the anterior superior mediastinum. She also
had a pulmonary mass at the left base posteriorly. The pa-
tientunderwentsternotomy,butthetumorwasunresectable.
Owing to the metastatic disease on presentation she opted
for chemotherapy alone. Since outcome is questionable and
therapy is toxic, she preferred to have Doxil therapy alone as
opposed to other agents. She had a complete remission after
3 cycles of Doxil therapy. Subsequent CT scans showed more
than 90% reduction in the size of her primary tumor and
resolution of the pulmonary metastasis. She had a disease-
free survival of 11 months. She then recurred with extensive
pulmonary metastasis and expired 16 months after initial di-
agnosis.
The liposomal delivery system has been developed to
avoid detection by the reticuloendothelial system (RES)
and to increase blood circulation time of doxorubicin.
Once inside the tumor, the liposomal covering allows re-
lease of the encapsulated doxorubicin. Within the cell, the
cytotoxic mechanism of action of doxorubicin is consistent
with conventionally delivered doxorubicin. Liposomal dox-
orubicin may be less susceptible to tumor resistance via
the multidrug resistance (MDR) mechanism that is me-
diated through an overexpression of a P170-glycoprotein
than conventional daunorubicin. However, further investi-
gations of PLD in soft tissue sarcoma are necessary [10,
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Studies using pegylated liposomal doxorubicin (PLD) in
the treatment of sarcomas at other sites have shown vari-
able results in response rates with improved toxicity proﬁle
and at least equivalent activity in comparison to doxorubicin
[12–14]. However, angiosarcomas in particular have unique
histopathological and biologic features compared to other
soft tissue sarcomas. PLD has also been used for the treat-
ment of Kaposis sarcoma in AIDS patients [15]. Both Kapo-
sis sarcoma and angiosarcoma are tumors of the endothe-
lial cells and therefore potentially share some common bi-
ologic properties [16]. Like angiosarcomas of other organs,
atrial angiosarcomas exhibit highly variable histologic pat-
terns, which often overlap those of Kaposi’s sarcoma, and
may also present metastatic patterns simulating widespread
Kaposi’s sarcoma. More recently, paclitaxel and liposomal
doxorubicin have been reported to have eﬃcacy in angiosar-
coma [17, 18]. We hypothesize that our patient might have
responded to liposomal doxorubicin because of its unique
activity in angiosarcoma in comparison to other sarcomas
and potential similarities with Kaposi’s sarcoma as described
in few other recent studies [19].
CONCLUSION
Due to the rarity of cardiac angiosarcoma there are no large
studies comparing diﬀerent chemotherapeutic regimens.
Several reports have demonstrated that PLD is at least as ac-
tive as free doxorubicin in soft tissue sarcomas. Notable, a re-
cent article report0 PLD is uniquely active in angiosarcoma.
OurcurrentcaseprovidesfurthersupportfortheroleofPLD
in the treatment of this rare tumor.
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